Targeted Genetics starts Phase II gene therapy study

TGEN began a 36-patient placebo controlled U.S. Phase II trial of its tgAAVCF adeno-associated virus (AAV) gene therapy product, which encodes the CFTR chloride transporter, to treat cystic fibrosis (...